Ozempic may reduce the mortality risk from colon cancer. Colon cancer patients taking GLP-1 drugs (Ozempic, Wegovy, Mounjaro) were less than half as likely to die within 5 years. This new study suggests GLP-1 drugs might specifically target obesity-driven inflammatory and metabolic pathways known to accelerate colon cancer progression. There are several mechanisms by which GLP-1 agonists may suppress tumor growth, including weight loss, improving glucose regulation and insulin sensitivity, and lowering inflammation. There is also some interesting in-vitro cell culture data indicating that these drugs may directly slow cancer cell proliferation, induce apoptosis, and remodel the tumor microenvironment itself. Exciting data. More research is needed. Study: